ThinkSabio

$ASND

$226.62▲ +0.1% YTD

7 SEC 13D/G filings tracked · Last updated Oct 16, 2026

Filing History
News
ASND ▲ +0.1% - Ascendis Pharma A/S
CP $226.62▲ +0.1%Oct 16, 2026 · ThinkSabio Blog

$ASND - Once-Weekly TransCon® CNP (Navepegritide) Receives Positive CHMP Opinion for the Treatment of Achondroplasia in Children…

News
ASND ▼ -0.0% - Ascendis Pharma A/S
CP $228.03▲ -0.0%Oct 6, 2026 · ThinkSabio Blog

$ASND - Ascendis to Share Latest Advances in Hypoparathyroidism and Achondroplasia Programs at ASBMR 2026…

News
ASND ▲ +1.3% - Ascendis Pharma A/S
CP $267.00▲ +1.3%Sep 14, 2026 · ThinkSabio Blog

$ASND - Ascendis Announces Planned $400 Million Share Repurchase Program…

News
ASND ▲ +1.3% - Ascendis Pharma A/S
CP $267.00▲ +1.3%Sep 14, 2026 · ThinkSabio Blog

$ASND - Ascendis to Regain Rights to TransCon® Technology in Metabolic and Cardiovascular Diseases…

News
ASND ▼ -3.4% - Ascendis Pharma A/S
CP $260.81▲ -3.4%Sep 9, 2026 · ThinkSabio Blog

$ASND - First Infant Data from Ascendis Trial of Once-Weekly TransCon CNP (Navepegritide) Presented at ESPE 2026…

News
ASND ▼ -0.2% - Ascendis Pharma A/S
CP $270.09▲ -0.2%Sep 8, 2026 · ThinkSabio Blog

$ASND - Ascendis Pharma to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference…

News
ASND ▲ +0.4% - Ascendis Pharma A/S
CP $249.00▲ +0.4%Aug 31, 2026 · ThinkSabio Blog

$ASND - Ascendis and BioMarin Enter Binding Term Sheet for a Global Settlement and License Agreement Related to YUVIWEL® (Navepegritide)…